title: Technical risks with subcutaneous insulin infusion.
abstract: The popularity of continuous subcutaneous insulin infusion (CSII), as a way for achieving long term strict glycaemic control in diabetic patients, has increased over the last ten years. Most reports on technical faults, often leading to metabolic emergencies, mainly ketoacidosis, have been published in the 1980s. Obstruction of infusion set and infection of infusion site are the most frequent events. Insulin precipitation or aggregation is thought to be one of the precipitating factors. Few data are available about failures of the pump itself. We report our experience of pump malfunctions recorded between 2001 and 2004 in 376 pumps used by patients treated with CSII therapy in Brittany. Recent studies indicate a decrease of metabolic complication frequency during CSII. This suggests technical improvements and/or a greater experience of physicians in selecting and educating patients. We report instructions for monitoring insulin pump therapy that should be included in a formal educational program for pump users. Clinical studies using newly available devices should reassess technical risks associated with CSII.
authors.affiliation: Unité de Diabétologie, CHU de Rennes, France. isabelle.guilhem@chu-rennes.fr
authors.forename: I
authors.initials: I
authors.lastname: Guilhem
authors.forename: A M
authors.initials: AM
authors.lastname: Leguerrier
authors.forename: F
authors.initials: F
authors.lastname: Lecordier
authors.forename: J Y
authors.initials: JY
authors.lastname: Poirier
authors.forename: D
authors.initials: D
authors.lastname: Maugendre
mesh_terms: D001786:Blood Glucose / Q000378:metabolism; D015190:Blood Glucose Self-Monitoring; D016883:Diabetic Ketoacidosis / Q000453:epidemiology; D004868:Equipment Failure; D006801:Humans; D007003:Hypoglycemia / Q000453:epidemiology; D007249:Inflammation; D007332:Insulin Infusion Systems / Q000009:adverse effects*; D012307:Risk Factors
chemical_list: D001786:Blood Glucose